Euroapi（0EAP）株式概要Euroapi S.A.は、フランス、欧州、その他の欧州地域、北米、アジア太平洋地域、および国際的に、ヒト用および動物用の医薬品の製剤化に使用される原薬および中間体の開発、製造、販売、流通を行っている。 詳細0EAP ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より10.5%で取引されている 収益は年間89.81%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析リスクチェックの結果、0EAP 、リスクは検出されなかった。すべてのリスクチェックを見る0EAP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW484,853 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG484,853 investors already sharing narrativesYour Fair Value€Current Price€1.2593.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-211m1b2016201920222025202620282031Revenue €834.3mEarnings €122.7mAdvancedSet Fair ValueView all narrativesEuroapi S.A. 競合他社ECO Animal Health GroupSymbol: AIM:EAHMarket cap: UK£61.0mAnimalcare GroupSymbol: AIM:ANCRMarket cap: UK£230.3mAllergy TherapeuticsSymbol: AIM:AGYMarket cap: UK£424.3mShield TherapeuticsSymbol: AIM:STXMarket cap: UK£66.2m価格と性能株価の高値、安値、推移の概要Euroapi過去の株価現在の株価€1.2552週高値€3.4152週安値€1.23ベータ0.981ヶ月の変化-0.79%3ヶ月変化-1.63%1年変化-61.39%3年間の変化-87.72%5年間の変化n/aIPOからの変化-91.50%最新ニュースお知らせ • Apr 23Euroapi S.A., Annual General Meeting, May 27, 2026Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris FranceBuy Or Sell Opportunity • Apr 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 40% to €1.29. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.Buy Or Sell Opportunity • Apr 01Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to €1.31. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.Buy Or Sell Opportunity • Mar 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 57% to €1.31. The fair value is estimated to be €1.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 3.9% in 2 years. Earnings are forecast to grow by 85% in the next 2 years.お知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.Reported Earnings • Mar 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €852.6m (down 7.2% from FY 2024). Net loss: €211.2m (loss widened 62% from FY 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom.最新情報をもっと見るRecent updatesお知らせ • Apr 23Euroapi S.A., Annual General Meeting, May 27, 2026Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris FranceBuy Or Sell Opportunity • Apr 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 40% to €1.29. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.Buy Or Sell Opportunity • Apr 01Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to €1.31. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.Buy Or Sell Opportunity • Mar 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 57% to €1.31. The fair value is estimated to be €1.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 3.9% in 2 years. Earnings are forecast to grow by 85% in the next 2 years.お知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.Reported Earnings • Mar 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €852.6m (down 7.2% from FY 2024). Net loss: €211.2m (loss widened 62% from FY 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom.Board Change • Jan 06Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Mattias Perjos was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Dec 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.4% to €3.16. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.Buy Or Sell Opportunity • Nov 24Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 5.6% to €3.22. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.Buy Or Sell Opportunity • Oct 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 2.5% to €3.19. The fair value is estimated to be €2.64, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.お知らせ • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.Buy Or Sell Opportunity • Oct 01Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 3.7% to €3.22. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.Reported Earnings • Jul 31First half 2025 earnings released: €0.30 loss per share (vs €0.37 loss in 1H 2024)First half 2025 results: €0.30 loss per share (improved from €0.37 loss in 1H 2024). Revenue: €414.5m (down 8.1% from 1H 2024). Net loss: €28.5m (loss narrowed 18% from 1H 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 22 percentage points per year, which is a significant difference in performance.お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026お知らせ • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€12m net loss in 3 years). Share price has been volatile over the past 3 months (8.2% average weekly change).お知らせ • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris FranceReported Earnings • Apr 05Full year 2024 earnings released: €1.38 loss per share (vs €2.01 loss in FY 2023)Full year 2024 results: €1.38 loss per share (improved from €2.01 loss in FY 2023). Revenue: €919.2m (down 9.8% from FY 2023). Net loss: €130.6m (loss narrowed 31% from FY 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom.New Risk • Mar 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €131m Forecast net loss in 3 years: €2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €919.2m (down 9.8% from FY 2023). Net loss: €130.6m (loss narrowed 31% from FY 2023). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.お知らせ • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.New Risk • Jan 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (€8.1m net loss in 3 years).New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€7.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change).Buy Or Sell Opportunity • Oct 19Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 8.8% to €3.32. The fair value is estimated to be €2.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period.お知らせ • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.お知らせ • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025Reported Earnings • Aug 02First half 2024 earnings released: €0.37 loss per share (vs €0.67 profit in 1H 2023)First half 2024 results: €0.37 loss per share (down from €0.67 profit in 1H 2023). Revenue: €450.9m (down 9.5% from 1H 2023). Net loss: €34.8m (down 155% from profit in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom.お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025New Risk • Jul 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €190m Forecast net loss in 3 years: €14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€161m). Currently unprofitable and not forecast to become profitable over next 3 years (€14m net loss in 3 years). Share price has been volatile over the past 3 months (7.8% average weekly change).お知らせ • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.お知らせ • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.Reported Earnings • Mar 01Full year 2023 earnings released: €2.01 loss per share (vs €0.16 loss in FY 2022)Full year 2023 results: €2.01 loss per share (further deteriorated from €0.16 loss in FY 2022). Revenue: €1.02b (up 3.9% from FY 2022). Net loss: €189.7m (loss widened €174.7m from FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.Valuation Update With 7 Day Price Move • Mar 01Investor sentiment deteriorates as stock falls 41%After last week's 41% share price decline to €3.95, the stock trades at a forward P/E ratio of 9x. Average trailing P/E is 34x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €6.51 per share.Buy Or Sell Opportunity • Mar 01Now 39% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to €3.95. The fair value is estimated to be €6.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Buy Or Sell Opportunity • Feb 06Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 19% to €6.03. The fair value is estimated to be €4.90, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.0% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.お知らせ • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.お知らせ • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.お知らせ • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.New Risk • Oct 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risk Large one-off items impacting financial results.Buying Opportunity • Oct 10Now 59% undervalued after recent price dropOver the last 90 days, the stock is down 51%. The fair value is estimated to be €12.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.お知らせ • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.お知らせ • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.お知らせ • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024株主還元0EAPGB PharmaceuticalsGB 市場7D-5.0%2.1%1.6%1Y-61.4%32.8%19.0%株主還元を見る業界別リターン: 0EAP過去 1 年間で32.8 % の収益を上げたUK Pharmaceuticals業界を下回りました。リターン対市場: 0EAPは、過去 1 年間で19 % のリターンを上げたUK市場を下回りました。価格変動Is 0EAP's price volatile compared to industry and market?0EAP volatility0EAP Average Weekly Movement5.8%Pharmaceuticals Industry Average Movement5.5%Market Average Movement5.4%10% most volatile stocks in GB Market10.7%10% least volatile stocks in GB Market2.9%安定した株価: 0EAP 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0EAPの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20202,961David Seignollewww.euroapi.com/enEuroapi S.A.は、フランス、ヨーロッパ、その他の欧州諸国、北米、アジア太平洋地域、および世界各国において、ヒト用および動物用医薬品の製剤に使用される医薬品有効成分および中間体の開発、製造、販売、流通を行っています。 同社は、固相化学、粒子工学、微生物発酵、低分子化合物の合成、プロスタグランジン、ステロイドおよびホルモン物質などを用いた、さまざまな種類の医薬品を対象とした受託開発製造（CDMO）サービスを提供しています。 また、ビタミンB12、プロスタグランジン、コルチコイドおよびホルモン、抗感染症薬、オピオイドおよび規制薬物、低分子および高分子化合物、中間体および試薬などの医薬品有効成分（API）ソリューションも提供しています。 同社の製品は、製薬業界の研究所、ジェネリック医薬品および動物用医薬品メーカー、コンシューマーヘルスケア企業、栄養食品企業、化粧品企業、バイオテクノロジー企業、受託開発・製造機関（CDMO）などに販売されています。Euroapi S.A.は2020年に設立され、フランス・パリに本社を置いています。もっと見るEuroapi S.A. 基礎のまとめEuroapi の収益と売上を時価総額と比較するとどうか。0EAP 基礎統計学時価総額€119.37m収益（TTM）-€211.20m売上高(TTM)€852.60m0.1xP/Sレシオ-0.6xPER（株価収益率0EAP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0EAP 損益計算書（TTM）収益€852.60m売上原価€707.70m売上総利益€144.90mその他の費用€356.10m収益-€211.20m直近の収益報告Dec 31, 2025次回決算日Jul 29, 2026一株当たり利益（EPS）-2.22グロス・マージン17.00%純利益率-24.77%有利子負債／自己資本比率5.8%0EAP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/08 22:44終値2026/07/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Euroapi S.A. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Justin Steven SmithBernsteinPatrick Andrew WoodBofA Global ResearchFynn ScherzlerDeutsche Bank8 その他のアナリストを表示
お知らせ • Apr 23Euroapi S.A., Annual General Meeting, May 27, 2026Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris France
Buy Or Sell Opportunity • Apr 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 40% to €1.29. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.
Buy Or Sell Opportunity • Apr 01Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to €1.31. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.
Buy Or Sell Opportunity • Mar 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 57% to €1.31. The fair value is estimated to be €1.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 3.9% in 2 years. Earnings are forecast to grow by 85% in the next 2 years.
お知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
Reported Earnings • Mar 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €852.6m (down 7.2% from FY 2024). Net loss: €211.2m (loss widened 62% from FY 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom.
お知らせ • Apr 23Euroapi S.A., Annual General Meeting, May 27, 2026Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris France
Buy Or Sell Opportunity • Apr 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 40% to €1.29. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.
Buy Or Sell Opportunity • Apr 01Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to €1.31. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years.
Buy Or Sell Opportunity • Mar 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 57% to €1.31. The fair value is estimated to be €1.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 3.9% in 2 years. Earnings are forecast to grow by 85% in the next 2 years.
お知らせ • Mar 05Euroapi S.A. Provides Earnings Guidance for the Fy 2026Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts.
Reported Earnings • Mar 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €852.6m (down 7.2% from FY 2024). Net loss: €211.2m (loss widened 62% from FY 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Board Change • Jan 06Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Mattias Perjos was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Dec 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.4% to €3.16. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
Buy Or Sell Opportunity • Nov 24Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 5.6% to €3.22. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
Buy Or Sell Opportunity • Oct 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 2.5% to €3.19. The fair value is estimated to be €2.64, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
お知らせ • Oct 02EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year.
Buy Or Sell Opportunity • Oct 01Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 3.7% to €3.22. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years.
Reported Earnings • Jul 31First half 2025 earnings released: €0.30 loss per share (vs €0.37 loss in 1H 2024)First half 2025 results: €0.30 loss per share (improved from €0.37 loss in 1H 2024). Revenue: €414.5m (down 8.1% from 1H 2024). Net loss: €28.5m (loss narrowed 18% from 1H 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 22 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report Fiscal Year 2025 Results on Mar 03, 2026Euroapi S.A. announced that they will report fiscal year 2025 results on Mar 03, 2026
お知らせ • Jul 02Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI).Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related to the company will be transferred to Particle Dynamics. The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements. Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025.
New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€12m net loss in 3 years). Share price has been volatile over the past 3 months (8.2% average weekly change).
お知らせ • Apr 17Euroapi S.A., Annual General Meeting, May 21, 2025Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France
Reported Earnings • Apr 05Full year 2024 earnings released: €1.38 loss per share (vs €2.01 loss in FY 2023)Full year 2024 results: €1.38 loss per share (improved from €2.01 loss in FY 2023). Revenue: €919.2m (down 9.8% from FY 2023). Net loss: €130.6m (loss narrowed 31% from FY 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom.
New Risk • Mar 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €131m Forecast net loss in 3 years: €2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €919.2m (down 9.8% from FY 2023). Net loss: €130.6m (loss narrowed 31% from FY 2023). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.
お知らせ • Mar 04Euroapi S.A. Provides Earnings Guidance for the Full Year 2025Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects.
New Risk • Jan 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (€8.1m net loss in 3 years).
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€7.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change).
Buy Or Sell Opportunity • Oct 19Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 8.8% to €3.32. The fair value is estimated to be €2.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period.
お知らせ • Oct 16+ 1 more updateEUROAPI Announces CFO ChangesOlivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. Olivier Falut joins EUROAPI with close to 30 years of experience in management and finance in the industrial sector. Throughout his career, he held various financial positions in listed and non-listed companies, such as Fareva, Limagrain (including Vilmorin & Cie), Lactalis and Bel. Olivier Falut started his career in the financial audit sector, mainly at Ernst & Young in France and then in the United States. In 2001, he joined Bosch France as head of accounting and pursued his career as accounting director at Bel in 2003. In 2008, he joined Oberthur Technologies as CFO for the main business unit before moving to Lactalis (2012-2017) as head of group financial control. Since 2017, he has held CFO positions in various companies including Sodiaal, Segula Technologies, Limagrain and Fareva. Olivier Falut is a graduate from ESSEC business school and holds master’s degrees in business law. He also graduated from the French bar exam.
お知らせ • Sep 13Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025
Reported Earnings • Aug 02First half 2024 earnings released: €0.37 loss per share (vs €0.67 profit in 1H 2023)First half 2024 results: €0.37 loss per share (down from €0.67 profit in 1H 2023). Revenue: €450.9m (down 9.5% from 1H 2023). Net loss: €34.8m (down 155% from profit in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom.
お知らせ • Jul 30+ 1 more updateEuroapi S.A. to Report First Half, 2025 Results on Jul 29, 2025Euroapi S.A. announced that they will report first half, 2025 results on Jul 29, 2025
New Risk • Jul 09New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €190m Forecast net loss in 3 years: €14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€161m). Currently unprofitable and not forecast to become profitable over next 3 years (€14m net loss in 3 years). Share price has been volatile over the past 3 months (7.8% average weekly change).
お知らせ • May 15+ 1 more updateEUROAPI Appoints Evelyne Nguyen as Chief Financial OfficerEvelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. Evelyne joins EUROAPI with over 30 years of experience in senior management and finance in the pharmaceutical and life science industries. Throughout her career, Eelyne held various finance, strategy, and management positions in listed and non-listed companies, such as Bristol Myers Squibb, SAUR, and LFB (Laboratoire Français du Fractionnement et des Biotechnologies). She has recently ssisted Biotech and Medtech companies with their strategic and financial projects. A graduate of ISG (Institut Supérieur de Gestion) and Stanford University Executive Program, Evelyne Nguyen started her career in Controlling and Finance for various international companies such as Coca-Cola and Schweppes. In 1987, she joined Bristol Myers Squibb France as a Business Planning and Financial Analysis Manager and pursued her career in Finance at SAUR (formerly Bouygues Group) in 1992. In 2007, she joined LFB, a biopharmaceutical company specialized in plasma derived medicinal products, and served during 12 years as CFO-Executive Vice President Finance and Strategy, supervising Strategic Planning, M&A, Corporate Finance, Internal Audit, and Information Systems. As a member of the Executive Committee, she was appointed Executive Vice President of Development and Biomanufacturing in 2010, in charge, notably, of CDMO business development, manufacturing scale up and strategic alliances. Evelyne has international experience with Europe, US and Asia. Since 2013, Evelyne Nguyen has worked as Finance, Strategy, and Business Development Advisor, supporting healthcare companies in several areas, including IPOs, debt and fund raising, strategic roadmap, business plan, and M&A.
お知らせ • Apr 10Euroapi S.A. Announces Executive and Executive Committee ChangesEUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer.
Reported Earnings • Mar 01Full year 2023 earnings released: €2.01 loss per share (vs €0.16 loss in FY 2022)Full year 2023 results: €2.01 loss per share (further deteriorated from €0.16 loss in FY 2022). Revenue: €1.02b (up 3.9% from FY 2022). Net loss: €189.7m (loss widened €174.7m from FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Mar 01Investor sentiment deteriorates as stock falls 41%After last week's 41% share price decline to €3.95, the stock trades at a forward P/E ratio of 9x. Average trailing P/E is 34x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €6.51 per share.
Buy Or Sell Opportunity • Mar 01Now 39% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to €3.95. The fair value is estimated to be €6.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Buy Or Sell Opportunity • Feb 06Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 19% to €6.03. The fair value is estimated to be €4.90, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.0% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.
お知らせ • Nov 29EUROAPI Announces Executive ChangesEUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar.
お知らせ • Nov 22Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company.
お知らせ • Oct 26+ 1 more updateEuroapi S.A. Announces Executive Changes, Effective October 30, 2023EUROAPI S.A’s Board of Directors met on October 25, 2023, and decided that Karl Rotthier will step down as Chief Executive Officer, effective October 30, 2023. The Board has launched a search for a new Chief Executive Officer. Consequently, it has appointed Viviane Monges, EUROAPI’s current Chair of the Board, as Chief Executive Officer until a permanent successor has been appointed. She will remain EUROAPI’s Chair of the Board. Viviane Monges is an experienced Finance Executive and Director and has worked in several business sectors and more than 25 years in the pharmaceutical industry. She served as Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then World Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, sheheld the position of Chief Financial Officer of the Global Pharma Business unit. She served on several Pharma companies' boards and is currently a member of the Board of Novo Holdings, Ferring Pharmaceuticals and Pharvaris.
New Risk • Oct 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risk Large one-off items impacting financial results.
Buying Opportunity • Oct 10Now 59% undervalued after recent price dropOver the last 90 days, the stock is down 51%. The fair value is estimated to be €12.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period.
お知らせ • Oct 10Euroapi S.A. Provides Sales Guidance for the Full-Year 2023Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues.
お知らせ • Aug 31Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million.Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.
Reported Earnings • Aug 02First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022)First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
お知らせ • Aug 01+ 2 more updatesEuroapi S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024Euroapi S.A. announced that they will report fiscal year 2023 results Pre-Market on Feb 29, 2024
